## Gilda A Neves

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5758906/publications.pdf

Version: 2024-02-01

28	801	14	23
papers	citations	h-index	g-index
30	30	30	1375
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Intermittent repeated stress but not ketamine changes mice response to antidepressants. Neuroscience Letters, 2021, 741, 135452.	1.0	4
2	Pharmacology of Drugs of Abuse: Pharmacokinetics and Pharmacodynamics of Psychotropic Compounds., 2021,, 109-127.		O
3	Energization by multiple substrates and calcium challenge reveal dysfunctions in brain mitochondria in a model related to acute psychosis. Journal of Bioenergetics and Biomembranes, 2020, 52, 1-15.	1.0	6
4	Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice. Psychopharmacology, 2020, 237, 1643-1655.	1.5	9
5	α7 nicotinic receptor full agonist reverse basolateral amygdala hyperactivity and attenuation of dopaminergic neuron activity in rats exposed to chronic mild stress. European Neuropsychopharmacology, 2019, 29, 1343-1353.	0.3	14
6	Zika virus replicates in adult human brain tissue and impairs synapses and memory in mice. Nature Communications, 2019, 10, 3890.	5.8	135
7	23.2 ALPHA 7 NICOTINIC MODULATORS REVERSE THE HYPERDOPAMINERGIC TONE IN THE MAM MODEL OF SCHIZOPHRENIA. Schizophrenia Bulletin, 2019, 45, S126-S126.	2.3	O
8	Design, synthesis and pharmacological evaluation of N -benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: Discovery of novel multi-target anti-alzheimer prototype drug candidates. European Journal of Medicinal Chemistry, 2018, 147, 48-65.	2.6	52
9	α7 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia. Neuropsychopharmacology, 2018, 43, 1712-1720.	2.8	18
10	S232. ALPHA7 NICOTINIC RECEPTOR AGONISTS REVERSE THE HYPERDOPAMINERGIC STATE IN THE MAM MODEL OF SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S416-S417.	2.3	0
11	Acute and chronic neurological consequences of early-life Zika virus infection in mice. Science Translational Medicine, 2018, 10, .	5.8	109
12	Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 130, 440-457.	2.6	67
13	Is Forced Swimming Immobility a Good Endpoint for Modeling Negative Symptoms of Schizophrenia? - Study of Sub-Anesthetic Ketamine Repeated Administration Effects. Anais Da Academia Brasileira De Ciencias, 2017, 89, 1655-1669.	0.3	8
14	Flavonoid Hesperidin Induces Synapse Formation and Improves Memory Performance through the Astrocytic TGF-Î <sup>2</sup> 1. Frontiers in Aging Neuroscience, 2017, 9, 184.	1.7	39
15	New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia. Behavioural Brain Research, 2013, 237, 86-95.	1.2	26
16	Pharmacokinetic evaluation of LASSBio-579: an <i>N</i> -phenylpiperazine antipsychotic prototype. Journal of Pharmacy and Pharmacology, 2010, 60, 699-707.	1.2	33
17	Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. Bioorganic and Medicinal Chemistry, 2010, 18, 1925-1935.	1.4	57
18	Design of new dopamine D2 receptor ligands: Biosynthesis and pharmacological evaluation of the hydroxylated metabolite of LASSBio-581. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2888-2891.	1.0	7

#	Article	lF	CITATION
19	Discovery of novel heteroarylazoleN-phenylpiperazine prototypes candidates to atypic antipsychotic drugs. Revista Virtual De Quimica, 2010, 2, .	0.1	0
20	Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581. Pharmacology Biochemistry and Behavior, 2008, 89, 23-30.	1.3	14
21	Hypnotic effect of ecdysterone isolated from Pfaffia glomerata (Spreng.) Pedersen. Revista Brasileira De Farmacognosia, 2008, 18, .	0.6	6
22	Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats. European Journal of Pharmaceutical Sciences, 2005, 26, 194-202.	1.9	11
23	Agentes dopaminérgicos e o tratamento da disfunção erétil. Quimica Nova, 2004, 27, 949-957.	0.3	2
24	Validated HPLC method for determination of LASSBio-581, a new heterocyclic N-phenylpiperazine derivative, in rat plasma. Journal of Pharmaceutical and Biomedical Analysis, 2003, 33, 1127-1133.	1.4	2
25	Design, synthesis and pharmacological profile of novel dopamine D2 receptor ligands. Bioorganic and Medicinal Chemistry, 2003, 11, 4807-4813.	1.4	67
26	Dopaminergic profile of new heterocyclic N-phenylpiperazine derivatives. Brazilian Journal of Medical and Biological Research, 2003, 36, 625-629.	0.7	32
27	Screening for the antidepressant activity of some species of Hypericum from South Brazil. Phytotherapy Research, 2000, 14, 344-346.	2.8	44
28	Psychopharmacological screening of Pfaffia glomerata Spreng. (Amarathanceae) in rodents. Journal of Ethnopharmacology, 2000, 73, 261-269.	2.0	39